"...new data have indicated the potential of these advances to alleviate a number of common disorders, including chemotherapy- induced and diabetic peripheral neuropathies, traumatic brain injury, and amyotrophic lateral sclerosis."
Interview with Ahmet Hoke, MD, PhD
AxoProtego Therapeutics Announces New CEO
Objective: Peripheral neurotoxicity is a major dose-limiting side effect of many chemotherapeutic drugs. Currently there are no effective disease-modifying therapies for chemotherapy-induced peripheral neuropathies, but these side effects of chemotherapy are potentially ideal targets for development of neuroprotective therapies, because candidate drugs can be co- or preadministered before the injury to peripheral axons takes place. (To read more click view publication)
AxoProtego Therapeutics Announces Novel Investigational Agent for Chemotherapy-Induced Peripheral Neuropathy
Trial designs for chemotherapy-induced peripheral neuropathy prevention3
Multi‐center assessment of the Total Neuropathy Score for chemotherapy‐induced peripheral neurotoxicity2
Development of a High-Throughput Screening Cancer Cell-Based Luciferase Refolding Assay for Identifying Hsp90 Inhibitors4
Safety and efficacy of ethoxyquin (6-ethoxy-1,2-dihydro-2,2,4-trimethylquinoline) for all animal species5
EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2015. Safety and efficacy of ethoxyquin (6‐ethoxy‐1,2‐dihydro‐2,2,4‐trimethylquinoline) for all animal species. EFSA Journal. 2015;13(11). doi:10.2903/j.efsa.2015.4272.
Ethoxyquin provides neuroprotection against cisplatin-induced neurotoxicity7
1 Błaszczyk A, Augustyniak A, Skolimowski J. Ethoxyquin: An Antioxidant Used in Animal Feed. International Journal of Food Science. 2013;2013:1-12. doi:10.1155/2013/585931.
2 Cavaletti G, Jann S, Pace A, et al. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. Journal of the Peripheral Nervous System. 2006;11(2):135-141. doi:10.1111/j.1085-9489.2006.00078.x.
3 Gewandter JS, Brell J, Cavaletti G, et al. Trial designs for chemotherapy-induced peripheral neuropathy prevention. Neurology. 2018;91(9):403-413. doi:10.1212/wnl.0000000000006083.
4 Sadikot T, Swink M, Eskew JD, et al. Development of a High-Throughput Screening Cancer Cell-Based Luciferase Refolding Assay for Identifying Hsp90 Inhibitors. ASSAY and Drug Development Technologies. 2013;11(8):478-488. doi:10.1089/adt.2012.498.
5 Safety and efficacy of ethoxyquin (6‐ethoxy‐1,2‐dihydro‐2,2,4‐trimethylquinoline) for all animal species. EFSA Journal. 2015;13(11). doi:10.2903/j.efsa.2015.4272.
6 Zhu J, Chen W, Mi R, Zhou C, Reed N, Höke A. Ethoxyquin prevents chemotherapy-induced neurotoxicity via Hsp90 modulation. Annals of Neurology. 2013;74(6):893-904. doi:10.1002/ana.24004.
7 Zhu J, Carozzi VA, Reed N, et al. Ethoxyquin provides neuroprotection against cisplatin-induced neurotoxicity. Scientific Reports. 2016;6(1). doi:10.1038/srep28861.